Dr. Davelyn Eaves Hood is the Vice President of Medical and Patient Affairs, where she unites her professional life as a physician with her personal experience as the mother of a child—now an adult—born with severe, diffuse congenital hyperinsulinism. This dual perspective gives her a unique understanding of the challenges, frustrations, and emotional toll faced by patients, families, and healthcare providers in managing this rare, life-threatening disease. Her professional career has included leadership roles spanning clinical practice, healthcare administration, and payer settings, and for nearly a decade prior to joining Rezolute, she dedicated many hours of volunteer time to Congenital Hyperinsulinism International (CHI), serving seven years as Board President. During this time with the international patient advocacy organization, Davelyn helped shape and launch cornerstone initiatives, such as the HI Global Registry and the CHI Centers of Excellence program. Through close collaboration with families, advocates, and clinicians around the world, she strived to ensure that patient perspectives guided these efforts, helping to increase disease awareness, expand patient-centered research, and improve care for the global congenital HI community—values she continues to bring to drug development at Rezolute.

Dana Jastrow serves as the Director of Patient Affairs at Rezolute, where she leads initiatives designed to engage, empower, and support rare-disease communities. She focuses on building trusted relationships with patients, caregivers, advocacy groups, and external partners to ensure that the lived experiences of those affected are meaningfully integrated into the company’s work. Dana began her career in the nonprofit sector before moving into the pharmaceutical industry, motivated by a strong commitment to connect patient voices with scientific innovation. With a deep appreciation for the challenges faced by rare-disease families, she works to make sure their perspectives guide the development of new therapies, particularly in areas where treatment options remain limited. As Rezolute prepares for commercialization, Dana plays a vital role in shaping inclusive, collaborative partnerships that keep patients at the center of the company’s mission. She welcomes connection with the hyperinsulinism community and invites anyone interested in Rezolute’s progress to reach out to her directly by email at [email protected].